🇺🇸 FDA
Patent

US 7517531

Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4

granted A61KA61K2039/5254A61K2039/5256

Quick answer

US patent 7517531 (Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
42
CPC classes
A61K, A61K2039/5254, A61K2039/5256, A61K2039/70, A61K39/12